Research Topics
| S A PlotkinSummaryAffiliation: Aventis Pharma Publications
| Collaborators
|
Detail Information
Publications
Conclusions to the conference on orphan vaccinesS A Plotkin
Aventis Pasteur, Doylestown, Philadelphia, PA 18901, USA
Dev Biol (Basel) 110:167-9. 2002
Vaccines in the 21st centuryStanley A Plotkin
Department of Pediatrics, University of Pennsylvania, Philadelphia, USA
Hybrid Hybridomics 21:135-45. 2002
Human cytomegalovirus vaccine is an orphanS A Plotkin
Aventis Pasteur, Doylestown, Philadelphia, PA 18901, USA
Dev Biol (Basel) 110:73-80. 2002
Lessons learned concerning vaccine safetyS A Plotkin
Wistar Institute, University of Pennsylvania, Aventis Pasteur, 4650 Wismer Road, Doylestown, PA 18901, USA
Vaccine 20:S16-9; discussion S1. 2001..Investigations that show the putative relationship to be incorrect serve as examples of scientific rigor, which are valuable for the public. The author draws eight lessons for the future from our recent experiences...
Postscript relating to new allegations made by Edward Hooper at The Royal Society Discussion Meeting on 11 September 2000S A Plotkin
University of Pennsylvania, Wistar Institute, 4650 Wismer Road, Doylestown, PA 18901, USA
Philos Trans R Soc Lond B Biol Sci 356:825-9. 2001..These were proposed as conclusive evidence for the hypothesis that simian immunodeficiency virus-contaminated CHAT polio vaccine caused the HIV-1 group M epidemic. We have investigated the facts in relation to these 'smoking guns'...
Untruths and consequences: the false hypothesis linking CHAT type 1 polio vaccination to the origin of human immunodeficiency virusS A Plotkin
University of Pennsylvania, Wistar Institute, 4650 Wismer Road, Doylestown, PA 18901, USA
Philos Trans R Soc Lond B Biol Sci 356:815-23. 2001..Testimony by eyewitnesses, documents of the time, epidemiological analysis, and ancillary phylogenetic, virologic and PCR data all concur to reject the hypothesis as false and without factual foundation...
CHAT oral polio vaccine was not the source of human immunodeficiency virus type 1 group M for humansS A Plotkin
University of Pennsylvania, Doylestown, PA, 18901, USA
Clin Infect Dis 32:1068-84. 2001..Testimony by eyewitnesses, historical documents of the time, epidemiological analysis, and analysis of ancillary phylogenetic, virological, and polymerase chain reaction data all indicate that this hypothesis is false...
Immunologic correlates of protection induced by vaccinationS A Plotkin
Aventis Pasteur, Doylestown, PA 18901, USA
Pediatr Infect Dis J 20:63-75. 2001..A condition for the efficacy of antibodies is functionality, i.e. their ability to kill or inactivate pathogens. The immune system is redundant, and the different types of responses to vaccines act synergistically...
Vaccines, vaccination, and vaccinologyStanley A Plotkin
Department of Pediatrics, University of Pennsylvania, Philadelphia, and Aventis Pasteur, Doylestown, Pennsylvania, USA
J Infect Dis 187:1349-59. 2003
Is there a formula for an effective CMV vaccine?Stanley A Plotkin
University of Pennsylvania, Wistar Institute, Aventis Pasteur, Doylestown, PA 18901, USA
J Clin Virol 25:S13-21. 2002
Safety and immunogenicity of the Towne strain cytomegalovirus vaccineS P Adler
Department of Pediatrics, Medical College of Virginia Virginia Commonwealth University, Richmond 23298 0163, USA
Pediatr Infect Dis J 17:200-6. 1998..Women with naturally acquired serum antibodies to cytomegalovirus (CMV) are usually protected against both frequent secondary infection and giving birth to infants severely affected by intrauterine CMV infection...
Vaccination against the major infectious diseasesS A Plotkin
University of Pennsylvania, Philadelphia, USA
C R Acad Sci III 322:943-51. 1999....
Vaccines in the 21st centuryS A Plotkin
Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Infect Dis Clin North Am 15:307-27. 2001..It is an optimistic vision, so let us hope that I am right...
[New vaccination strategies]Stanley A Plotkin
Sanofi Pasteur, 4650 Wismer Road, Doylestown, PA 18902, USA
Bull Acad Natl Med 192:511-8; discussion 518-9. 2008..Also, new methods of vaccine delivery besides injection will be used and new adjuvants will be added to vaccines in order to stimulate specific responses. The future of vaccination is promising...
Commentary: congenital rubella syndrome should not be a disease of poor countriesStanley A Plotkin
University of Pennsylvania and Aventis Pasteur, Doylestown, PA 18901, USA
Pediatr Infect Dis J 23:1123-4. 2004
Vaccines: past, present and futureStanley A Plotkin
Sanofi Pasteur and the University of Pennsylvania, 4650 Wismer Road, Doylestown, Pennsylvania 18901, USA
Nat Med 11:S5-11. 2005..With all this come new problems in the production, regulation and distribution of vaccines...
Congenital cytomegalovirus infection and its preventionStanley A Plotkin
Clin Infect Dis 38:1038-9. 2004
Natural vs vaccine-acquired immunity to cytomegalovirusStanley A Plotkin
JAMA 290:1709; author reply 1709. 2003
The history of rubella and rubella vaccination leading to eliminationStanley A Plotkin
Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA
Clin Infect Dis 43:S164-8. 2006..The present article summarizes the clinical syndrome of CRS, the process by which the vaccine was developed, and the history leading up to elimination, as well as the possible extension of elimination on a wider scale...
Six revolutions in vaccinologyStanley A Plotkin
University of Pennsylvania, Philadelphia, PA, USA
Pediatr Infect Dis J 24:1-9. 2005..I propose new delivery systems as the most likely to succeed, although humbly admitting that prediction is always subject to error...
Why certain vaccines have been delayed or not developed at allStanley A Plotkin
University of Pennsylvania, Philadelphia, PA, USA
Health Aff (Millwood) 24:631-4. 2005..However, to take things further, there must be a vaccine manufacturer, a regulatory authority ready to give permission for the use of the vaccine, and public health authorities that will recommend and foster vaccination...
Varicella vaccination in Japan, South Korea, and EuropeCatherine Sadzot-Delvaux
Unit of Fundamental Virology and Immunology, Department of Life Sciences, University of Liege, Sart Tilman, Belgium
J Infect Dis 197:S185-90. 2008..The recent development of a tetravalent vaccine against measles, mumps, rubella, and varicella could modify this variability in the future. It is evident that efforts to control varicella will spread gradually to all continents...
Vaccines: correlates of vaccine-induced immunityStanley A Plotkin
Sanofi Pasteur, Doylestown, Pennsylvania, USA
Clin Infect Dis 47:401-9. 2008..In situations where the true correlate of protection is unknown or difficult to measure, surrogate tests (usually antibody measurements) must suffice as predictors of protection by vaccines. Examples of each circumstance are given...
Of vaccination and infectious diseases in 2003Stanley A Plotkin
University of Pennsylvania, USA
Adv Exp Med Biol 549:1-4. 2004
Chimpanzees and journalistsStanley A Plotkin
Vaccine 22:1829-30. 2004
Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedulesIsabelle Parent Du Chatelet
Association pour l Aide a la Medecine Preventive, 25 rue du Dr Roux, 75724 Cedex 15, Paris, France
Vaccine 21:1710-8. 2003..Combined schedules of OPV and IPV in the form of diphtheria-pertussis-tetanus-IPV vaccine (DPT-IPV) may be useful to accelerate eradication of polio in developing countries...
An epidemic of inhalation anthrax, the first in the twentieth century: I. Clinical features. 1960Stanley A Plotkin
Am J Med 112:4-12; discussion 2-3. 2002
The cost of not implementing routine neonates immunization programmes in HBsAg high prevalence countriesPierre Chauvin
Vaccine 20:2848-50. 2002
The late sequelae of ArrowsmithStanley A Plotkin
Medical and Scientific Advisor, Aventis Pasteur, Swiftwater, PA 18370, USA
Pediatr Infect Dis J 21:807-9. 2002
